Delivery Order SPE2DB20D1109-SPE2DB25FP29Y
- Not listed
- The Defense Logistics Agency awarded a $4,622.87 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 26, 2025. This non-set-aside contract employs firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $1,801.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of June 2, 2025. This non-set-aside, competitively awarded contract represents a single delivery order fulfilling pharmaceutical supply requirements for federal healthcare systems. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 29, 2025. This non-competitive delivery order represents a firm fixed price transaction and is classified as a child contract under AmerisourceBergen's larger contract vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,115.57, with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger federal contract vehicle. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a $3,903.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery...
- The Defense Logistics Agency awarded a $3,682.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 22, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order executes under...
- The Defense Logistics Agency (DLA) awarded a $1,089.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is a child order under a larger vehicle, was competitively awarded without a set-aside designation and carries an ultimate completion date of September 5, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP29YDelivery Order
The Defense Logistics Agency awarded a $4,138.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens with an ultimate completion date of June 27, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a critical pharmaceutical distributor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical products to support military and veteran healthcare systems worldwide. The NovoLog delivery supports diabetes management requirements across the Defense Health Agency and other federal healthcare customers, demonstrating the company's role as a prime vendor for specialty medications and injectable pharmaceutical products within the DLA's global pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 6/26/25 |